UBS Group’s Altimmune ALT Stock Holding History

UBS Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,100	Closed	-$103K	–	10690
2022 Q3	$103K	Buy	+8,100	New	+$120K	﹤0.01%	5676

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS Group's ALT Position: Q1 2026 in Review

UBS Group increased its Altimmune (ALT) stake by 41% in Q1 2026, buying an estimated $1.12M and bringing the position to 904,768 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4664.

UBS Group first reported a position in ALT in Q4 2014 and has held it in 42 quarters since. The position peaked at $15.8M in Q4 2020. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

UBS Group held 904,768 shares of Altimmune worth $2.79M as of Q1 2026.
UBS Group bought 262,720 Altimmune shares in Q1 2026, an estimated $1.12M.
Altimmune made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4664 holding.
UBS Group first reported a position in Altimmune in Q4 2014 and has held it in 42 quarters since.
UBS Group's Altimmune position peaked at $15.8M in Q4 2020.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.